Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Co-treatment with letrozole during ovarian stimulation for IVF/ICSI: a systematic review and meta-analysis

Research output: Contribution to journalReviewpeer-review

  1. Reintroducing serum FSH measurement during ovarian stimulation for ART

    Research output: Contribution to journalJournal articlepeer-review

  2. Clusters of smooth endoplasmic reticulum are absent in oocytes from unstimulated women

    Research output: Contribution to journalJournal articlepeer-review

  3. Stress and depression among women and men who have experienced recurrent pregnancy loss: focusing on both sexes

    Research output: Contribution to journalJournal articlepeer-review

  4. Empathetic application of machine learning may address appropriate utilization of ART

    Research output: Contribution to journalJournal articlepeer-review

View graph of relations

Letrozole reduces serum oestradiol by inhibiting the aromatase enzyme and has growing clinical indications in fertility. The available evidence of letrozole's role in ovarian stimulation for IVF and intracytoplasmic sperm injection (ICSI) and clinical outcomes was assessed. Medline, Cochrane, and databases were systematically searched up until August 2021, including 31 studies (n = 16 randomized controlled trials [RCTs]; n = 15 observational studies). Live birth rate (LBR) in poor responders significantly increased by 7% (95% CI, 1% to 13%, P = 0.03) with letrozole co-treatment. Concomitantly, the gonadotrophin consumption was significantly reduced, without decreasing the number of retrieved oocytes. In normal responders, number of oocytes increased with 1.8 oocytes (95% CI 0.35 to 3.27, P = 0.01) with letrozole co-treatment. No significant effect on LBR, clinical pregnancy rate (CPR), or ovarian hyperstimulation syndrome rate was demonstrated. Only two studies reported on high responders and revealed no effect on LBR or CPR. Overall, the endometrium thickness was slightly affected, where as the, miscarriage rate and cancellation rate were unaffected by letrozole co-treatment. None of the included studies reported on neonatal outcomes. The quality of evidence was high or moderate in the RCTs and low in the observational studies. In conclusion, poor responders may benefit from co-treatment with letrozole during ovarian stimulation for IVF, whereas letrozole for normal and high responders requires further investigation with larger, high-quality studies.

Original languageEnglish
JournalReproductive BioMedicine Online
Issue number4
Pages (from-to)717-736
Number of pages20
Publication statusPublished - Apr 2022

Bibliographical note

Publisher Copyright:
© 2021 Reproductive Healthcare Ltd.

    Research areas

  • Female, Fertilization in Vitro, Humans, Letrozole/therapeutic use, Live Birth, Ovulation Induction, Pregnancy, Pregnancy Rate, Sperm Injections, Intracytoplasmic

ID: 75919743